News | I Peace, Inc

News

GMP cell CDMO I Peace, Inc. in collaboration with universities successfully converted human dermal fibroblasts into oligodendrocyte by direct reprogramming

•

September 20, 2022

•

Other

A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously
To be presented at ISSCR 2022 Annual Meeting

•

June 15, 2022

•

Uncategorized

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

•

May 12, 2022

•

Other

I Peace triples GMP cell manufacturing by expanding CDMO facility

•

March 14, 2022

•

Uncategorized

I Peace’s Cell Manufacturing Facility “Peace Engine-Kyoto”now registered as U.S. FDA Drug Establishment

•

January 26, 2022

•

Press, Press, Press, Press, Press

[Summary of Research]Anti-cancer therapeutic potential of tumoricidal T cells regenerated from tumor-infiltrating lymphocyte-derived iPS cells

•

October 19, 2021

•

Uncategorized

Koji Tanabe, CEO of I Peace, Inc.
honored by World Biz Magazine with
the “ Top 100 Innovation CEO” Award

•

September 22, 2021

•

Uncategorized

Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability

•

September 7, 2021

•

Uncategorized

[Summary of Research]The iPSC-based cancer vaccine prevents tumor growth in pancreatic cancer

•

July 9, 2021

•

Other, Other, Other

I Peace’s cell manufacturing facility “Peace Engine Kyoto” receives third-party certification as US cGMP compliant: the facility now meets the standard
for both the US and Japanese markets

•

May 25, 2021

•

Uncategorized

Reach out to us to learn more